Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 108, Issue 2, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2023.116139
Keywords
Cytomegalovirus (CMV); T-cells; CD4+T-cells; CD8+T-cells
Categories
Ask authors/readers for more resources
This study evaluated the performance of the Viracor CMV-T-cell immunity Panel (TCIP) in predicting CMV events. The results showed that CMV-specific CD4+ and CD8(+)T-cells were significantly lower in those with CMV events, and the TCIP could be a useful adjunct tool in individualized management of CMV infection.
The Viracor CMV-T-cell immunity Panel (TCIP) measures %CMV-specific CD4+ and CD8(+) T-cells. In this blinded clinical study, we evaluated the performance of the TCIP in predicting CMV events. Prospectively enrolled donor or recipient CMV-seropositive kidney transplant recipients (KTR) were evaluated with monthly TCIP testing until either discontinuation of valganciclovir prophylaxis or CMV DNAemia prompting treatment initiation. Also, prospectively enrolled KTR with low-level untreated DNAemia or after completion of treatment were evaluated for progression or relapse of CMV infection. Among 46 KTR, those with CMV events had significantly lower % CMV-specific CD8(+)T-cells (p = 0.024), and the CMV protection ROC AUC was significant (AUC 0.78, p = 0.026). The positive predictive values of CD4+ and CD8(+) T-cell positivity >0.2 % for CMV protection were: 96.3 % for CMV DNAemia prompting treatment initiation, 92.6 % for any DNAemia, 100 % for DNAemia >1000 IU/mL. The TCIP could be a useful adjunct tool in individualized management of CMV infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available